|
Q3 FY2026
As of Jul 31, 2026
|
Q2 FY2026
As of Apr 30, 2026
|
Q1 FY2026
As of Jan 31, 2026
|
Q4 FY2025
As of Oct 31, 2025
|
Q3 FY2025
As of Jul 31, 2025
|
Q2 FY2025
As of Apr 30, 2025
|
Q1 FY2025
As of Jan 31, 2025
|
Q4 FY2024
As of Oct 31, 2024
|
Q3 FY2024
As of Jul 31, 2024
|
Q2 FY2024
As of Apr 30, 2024
|
Q1 FY2024
As of Jan 31, 2024
|
Q4 FY2023
As of Oct 31, 2023
|
Q3 FY2023
As of Jul 31, 2023
|
Q2 FY2023
As of Apr 30, 2023
|
Q1 FY2023
As of Jan 31, 2023
|
Q4 FY2022
As of Oct 31, 2022
|
Q3 FY2022
As of Jul 31, 2022
|
Q2 FY2022
As of Apr 30, 2022
|
Q1 FY2022
As of Jan 31, 2022
|
Q4 FY2021
As of Oct 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Cash, cash equivalents and restricted cash | ||||||||||||||||||||
| Accounts receivable, net of allowance for credit losses of $57 and $83 as of July 31, 2026 and October 31, 2025 | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other non-current assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Notes payable and short-term borrowings | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Other non-current liabilities | ||||||||||||||||||||
| Stockholders’ deficit: | ||||||||||||||||||||
| Preferred stock, $0.01 par value (300 shares authorized; none issued) | ||||||||||||||||||||
| Common stock, $0.01 par value (9,600 shares authorized; 980 and 989 shares issued and outstanding at January 31, 2024 and October 31, 2023, respectively) | ||||||||||||||||||||
| Common stock, $0.01 par value (9,600 shares authorized; 903 and 921 shares issued and outstanding as of July 31, 2026 and October 31, 2025) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders’ deficit | ||||||||||||||||||||
| Total liabilities and stockholders’ deficit |
Loading...
